Capitolis Liquid Global Markets LLC Acquires 49,000 Shares of Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN)

Capitolis Liquid Global Markets LLC increased its holdings in shares of Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN - Free Report) by 128.9% during the fourth quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The fund owned 87,000 shares of the biopharmaceutical company's stock after acquiring an additional 49,000 shares during the quarter. Capitolis Liquid Global Markets LLC owned about 0.08% of Regeneron Pharmaceuticals worth $61,973,000 as of its most recent SEC filing.

Other hedge funds have also added to or reduced their stakes in the company. Principal Financial Group Inc. grew its position in shares of Regeneron Pharmaceuticals by 1.7% in the third quarter. Principal Financial Group Inc. now owns 173,092 shares of the biopharmaceutical company's stock valued at $181,961,000 after purchasing an additional 2,828 shares during the last quarter. Nordea Investment Management AB lifted its position in Regeneron Pharmaceuticals by 23.6% during the fourth quarter. Nordea Investment Management AB now owns 42,667 shares of the biopharmaceutical company's stock worth $30,160,000 after purchasing an additional 8,135 shares during the period. Diversified Trust Co grew its stake in Regeneron Pharmaceuticals by 93.0% during the fourth quarter. Diversified Trust Co now owns 2,330 shares of the biopharmaceutical company's stock worth $1,660,000 after buying an additional 1,123 shares in the last quarter. Range Financial Group LLC bought a new position in Regeneron Pharmaceuticals in the 4th quarter valued at about $220,000. Finally, First Hawaiian Bank raised its position in shares of Regeneron Pharmaceuticals by 18.8% in the 4th quarter. First Hawaiian Bank now owns 2,995 shares of the biopharmaceutical company's stock valued at $2,133,000 after buying an additional 474 shares in the last quarter. Institutional investors and hedge funds own 83.31% of the company's stock.

Wall Street Analyst Weigh In

A number of equities analysts recently issued reports on the stock. Sanford C. Bernstein lowered their price objective on shares of Regeneron Pharmaceuticals from $1,110.00 to $1,070.00 and set an "outperform" rating for the company in a research report on Tuesday, January 7th. Guggenheim cut their target price on Regeneron Pharmaceuticals from $940.00 to $810.00 and set a "buy" rating on the stock in a research report on Thursday, May 1st. JPMorgan Chase & Co. decreased their price objective on Regeneron Pharmaceuticals from $1,100.00 to $1,000.00 and set an "overweight" rating for the company in a report on Monday, March 31st. Bernstein Bank lowered their target price on shares of Regeneron Pharmaceuticals from $1,070.00 to $1,000.00 in a report on Tuesday, February 4th. Finally, Wells Fargo & Company cut their price target on shares of Regeneron Pharmaceuticals from $750.00 to $700.00 and set an "overweight" rating on the stock in a report on Wednesday, April 30th. One analyst has rated the stock with a sell rating, five have given a hold rating, eighteen have issued a buy rating and three have assigned a strong buy rating to the stock. Based on data from MarketBeat.com, Regeneron Pharmaceuticals has a consensus rating of "Moderate Buy" and an average target price of $892.60.

Regeneron Pharmaceuticals Trading Down 0.3 %

Shares of REGN opened at $603.58 on Tuesday. The stock has a market capitalization of $65.99 billion, a PE ratio of 15.77, a P/E/G ratio of 2.34 and a beta of 0.43. The company's fifty day moving average is $624.42 and its 200 day moving average is $704.67. The company has a debt-to-equity ratio of 0.09, a quick ratio of 3.95 and a current ratio of 4.73. Regeneron Pharmaceuticals, Inc. has a fifty-two week low of $525.99 and a fifty-two week high of $1,211.20.

Regeneron Pharmaceuticals (NASDAQ:REGN - Get Free Report) last announced its quarterly earnings results on Tuesday, April 29th. The biopharmaceutical company reported $8.22 EPS for the quarter, missing analysts' consensus estimates of $8.83 by ($0.61). Regeneron Pharmaceuticals had a net margin of 31.07% and a return on equity of 16.32%. The business had revenue of $3.03 billion during the quarter, compared to the consensus estimate of $3.40 billion. During the same period in the previous year, the business posted $9.55 EPS. The firm's revenue was down 3.7% on a year-over-year basis. Sell-side analysts expect that Regeneron Pharmaceuticals, Inc. will post 35.92 earnings per share for the current fiscal year.

Regeneron Pharmaceuticals Announces Dividend

The firm also recently declared a quarterly dividend, which will be paid on Friday, June 6th. Investors of record on Tuesday, May 20th will be paid a dividend of $0.88 per share. This represents a $3.52 dividend on an annualized basis and a dividend yield of 0.58%. The ex-dividend date is Tuesday, May 20th. Regeneron Pharmaceuticals's dividend payout ratio is currently 8.96%.

About Regeneron Pharmaceuticals

Regeneron Pharmaceuticals, Inc discovers, invents, develops, manufactures, and commercializes medicines for treating various diseases worldwide. The company's products include EYLEA injection to treat wet age-related macular degeneration and diabetic macular edema; myopic choroidal neovascularization; diabetic retinopathy; neovascular glaucoma; and retinopathy of prematurity.

Want to see what other hedge funds are holding REGN? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.